文献速递神经肿瘤

选择性BCL-XL抑制与MLN8237联合在髓母细胞瘤和儿童胶质母细胞瘤细胞中促进凋亡

Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.
PubMed 文献 · Neuro Oncol · 2018-01-01

本研究在髓母细胞瘤和儿童胶质母细胞瘤细胞中探讨BCL-2家族抑制剂ABT-263、ABT-199、WEHI-539与Aurora激酶抑制剂MLN8237联合的效应。ABT-263联合MLN8237减少有丝分裂滑脱和多倍体,经BAX/BAK依赖性caspase介导凋亡途径促进清除有丝分裂缺陷细胞。BCL-XL拮抗剂WEHI-539联合MLN8237显著增强肿瘤细胞杀伤,并使耐药脑肿瘤细胞对新型BAX激活剂SMBA1敏感。

要点

  • ABT-263联合MLN8237减少有丝分裂滑脱和多倍体,经BAX/BAK依赖性caspase介导途径促进凋亡。
  • BCL-XL拮抗剂WEHI-539联合MLN8237显著增强肿瘤细胞杀伤。
  • WEHI-539使耐药脑肿瘤细胞对新型BAX激活剂SMBA1敏感。

核心结论

  • 选择性小分子BCL-XL抑制剂可能增强MLN8237和其他靶向化疗药物的疗效。

研究设计与样本

  • 体外研究,在髓母细胞瘤和儿童胶质母细胞瘤细胞中检测BCL-2家族抑制剂ABT-263、ABT-199和WEHI-539与Aurora激酶抑制剂MLN8237联合的效应。

主要发现

  • ABT-263联合MLN8237减少有丝分裂滑脱和多倍体,并通过BAX/BAK依赖性、caspase介导的凋亡途径促进有丝分裂缺陷细胞的清除。
  • BCL-XL拮抗剂WEHI-539与MLN8237联合时显著增强肿瘤细胞杀伤。
  • WEHI-539使耐药脑肿瘤细胞对新型BAX激活剂SMBA1敏感。
  • siRNA介导的BCL-XL敲低使儿童胶质母细胞瘤和髓母细胞瘤细胞对MLN8237敏感,并模拟联合药物处理的效应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CNS tumors, including medulloblastoma and pediatric glioblastoma (pGBM) account for the majority of solid pediatric malignancies. There remains an unmet need to identify novel treatment approaches in poor prognosis and relapsed pediatric brain tumors, where therapeutic options are limited. Small-molecule B-cell lymphoma 2 (BCL-2) family inhibitors may enhance tumor cell killing when combined with conventional and targeted chemotherapeutic agents. We investigated the effect of disrupting BCL-2 and B cell lymphoma-extra large (BCL-XL) protein function using ABT-263, ABT-199 and WEHI-539 in medulloblastoma and pGBM cells following treatment with MLN8237, an Aurora kinase inhibitor under investigation as a novel agent for the treatment of malignant brain tumors. METHODS: Tumor cell growth and viability were determined by MTT/WST-1 assays and flow cytometry. Effects on cell phenotype, cell cycle progression, and ploidy were determined by live cell imaging and DNA content analysis. Apoptosis was determined by annexin V/propidium iodide staining and time-lapse microscopy and confirmed by measuring caspase-3/7 activity and western blotting and by short interfering RNA (siRNA) knockdown of BCL-2 associated X protein/BCL-2 antagonist killer (BAX/BAK). RESULTS: ABT-263, in combination with MLN8237, reduced mitotic slippage and polyploidy and promoted the elimination of mitotically defective cells via a BAX/BAK-dependent, caspase-mediated apoptotic pathway. The BCL-XL antagonist, WEHI-539, significantly augmented tumor cell killing when used in combination with MLN8237, as well as sensitized resistant brain tumor cells to a novel BAX activator, SMBA1. In addition, siRNA-mediated knockdown of BCL-XL sensitized pGBM and medulloblastoma cells to MLN8237 and mimicked the effect of combination drug treatment. CONCLUSION: Selective small-molecule inhibitors of BCL-XL may enhance the efficacy of MLN8237 and other targeted chemotherapeutic agents.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Levesley J, Steele L, Brüning-Richardson A, et al. Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells. Neuro Oncol. 2018. PMID: 29016820. doi:10.1093/neuonc/nox134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。